Amgen Inc. AMGN
414.61
8.57
2.11%
as of 25 Sep
- Market cap
- $219.1B
- P/E
- 25.6×
Follow AMGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Amgen Inc. (AMGN) P/S ratio
As of 25 September 2026, Amgen Inc. (AMGN) trades at a P/S ratio of 5.9×. Over the past ten years it has ranged from 4.1× (May 2025) to 6.5× (July 2015); the current reading is higher than 90% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 4.8× | 14.42% |
| FY2024 | 4.2× | (25.81%) |
| FY2023 | 5.6× | 5.54% |
| FY2022 | 5.3× | 8.34% |
| FY2021 | 4.9× | (6.86%) |
| FY2020 | 5.3× | (15.11%) |
| FY2019 | 6.2× | 15.21% |
| FY2018 | 5.4× | (4.31%) |
| FY2017 | 5.7× | 15.47% |
| FY2016 | 4.9× | (13.67%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 5.1× | 0.55% |
| Mar 2026 | 5.1× | 6.54% |
| Dec 2025 | 4.8× | 13.52% |
| Sep 2025 | 4.2× | (1.89%) |
| 42 more quarters | Free account |
Against its own ten years
Low 4.1×
High 6.5×
Ten-year median
5.3×
Current reading's percentile
90
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PFE Pfizer Inc. compare | 2.6× |
| BMY Bristol Myers Squibb Company compare | 2.6× |
| NVO Novo Nordisk A/S compare | 3.3× |
| AZN AstraZeneca PLC compare | 4.2× |
| NVS Novartis AG compare | 4.9× |
| MRK Merck & Co., Inc. compare | 5.5× |
| AMGN Amgen Inc. | 5.9× |
| GILD Gilead Sciences, Inc. compare | 6.2× |
| ABBV AbbVie Inc. compare | 7.3× |
| Drug Manufacturers General industry median | 3.3× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on AMGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement